Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Sees Large Growth in Short Interest

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) saw a significant growth in short interest in October. As of October 31st, there was short interest totalling 5,100,000 shares, a growth of 7.8% from the October 15th total of 4,730,000 shares. Based on an average trading volume of 191,600 shares, the short-interest ratio is presently 26.6 days. Currently, 25.2% of the company's stock are sold short.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of large investors have recently made changes to their positions in the company. Bain Capital Life Sciences Investors LLC bought a new stake in shares of Dianthus Therapeutics in the first quarter valued at approximately $89,761,000. RA Capital Management L.P. acquired a new stake in shares of Dianthus Therapeutics during the 1st quarter worth $69,990,000. Janus Henderson Group PLC increased its position in shares of Dianthus Therapeutics by 40.5% in the third quarter. Janus Henderson Group PLC now owns 949,334 shares of the company's stock worth $25,936,000 after purchasing an additional 273,670 shares during the period. State Street Corp raised its stake in Dianthus Therapeutics by 101.4% in the third quarter. State Street Corp now owns 821,131 shares of the company's stock valued at $22,483,000 after purchasing an additional 413,425 shares in the last quarter. Finally, Great Point Partners LLC lifted its holdings in shares of Dianthus Therapeutics by 21.3% during the 2nd quarter. Great Point Partners LLC now owns 757,929 shares of the company's stock worth $19,615,000 after acquiring an additional 132,929 shares during the period. Institutional investors own 47.53% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on DNTH. Wedbush reduced their target price on shares of Dianthus Therapeutics from $38.00 to $36.00 and set an "outperform" rating for the company in a research note on Friday, August 9th. Baird R W upgraded Dianthus Therapeutics to a "strong-buy" rating in a research note on Friday, July 26th. Robert W. Baird initiated coverage on shares of Dianthus Therapeutics in a research report on Friday, July 26th. They issued an "outperform" rating and a $58.00 target price for the company. Oppenheimer upped their target price on Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an "outperform" rating in a report on Monday, November 11th. Finally, Raymond James upped their price objective on Dianthus Therapeutics from $51.00 to $56.00 and gave the stock an "outperform" rating in a research note on Friday, November 8th. Eight research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $46.43.

Dianthus Therapeutics Price Performance

DNTH stock traded down $1.33 during midday trading on Tuesday, reaching $22.27. 184,561 shares of the company were exchanged, compared to its average volume of 205,644. The firm has a market capitalization of $659.19 million, a price-to-earnings ratio of -8.91 and a beta of 1.84. The business has a 50-day moving average price of $27.39 and a two-hundred day moving average price of $26.68. Dianthus Therapeutics has a one year low of $6.58 and a one year high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing analysts' consensus estimates of ($0.59) by ($0.15). The company had revenue of $2.17 million during the quarter, compared to analyst estimates of $1.07 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. As a group, analysts anticipate that Dianthus Therapeutics will post -2.61 earnings per share for the current fiscal year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.